Myriad Genetics, Inc. (MYGN)

24,66 +0,14 (+0,57%) Al cierre: 04:00PM EDT

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 2700

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Paul J. Diaz	CEO, President & Director	2,31M	N/A	1962
Mr. Samraat S. Raha	Chief Operating Officer	514,76k	N/A	1973
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer	816,5k	N/A	1980
Mr. Mark S. Verratti	Chief Commercial Officer	915,81k	N/A	1968
Mr. Scott J. Leffler	Chief Financial Officer	N/A	N/A	1975
Ms. Natalie Munk	Principal Accounting Officer	N/A	N/A	1981
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer	580,36k	N/A	1986
Mr. Matthew Scalo	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Justin Hunter	Interim General Counsel & Corporate Secretary	N/A	N/A	N/A
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Gobierno corporativo

El ISS Governance QualityScore de Myriad Genetics, Inc., a día 1 de junio de 2024, es 3. Las puntuaciones base son Auditoría: 8; Tablero: 2; Derechos de los accionistas: 5; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.